- cafead Apr 05, 2021 at 10:23: PM
via Gilead Sciences didn't bring CEO Dan O’Day on board to usher a COVID-19 antiviral to an FDA approval, but his company’s success in that arena certainly lifted Gilead's fortunes last year. Still, the CEO’s pay package fell quite dramatically year-over-year, thanks to one-time payments he collected in 2019 as an incentive to join the drugmaker.
article source
article source